Clyde Michael Jones MD MSc , FACP

Oncology•Memphis, TN

Hematologic Oncology, Melanoma

The Jones Clinic, PC - C. Michael Jones, M.D

Join to View Full Profile

1030 Jefferson AveMemphis VAMemphis, TN 38104
Phone+1 901-523-5990
Fax+1 901-751-6170

Education & Training

London School of Economics and Political ScienceMS, Health Economics, Ms, 2012 - 2014
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1978 - 1978
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1977 - 1978
Johns Hopkins UniversityResidency, Internal Medicine, 1976 - 1977
University of Alabama Medical CenterResidency, Internal Medicine, 1974 - 1976
University of Alabama School of MedicineClass of 1974

Certifications & Licensure

MD State Medical License 1976 - 2026
MS State Medical License 1998 - 2026
AL State Medical License 1975 - 2025
GA State Medical License 2024 - 2025
LA State Medical License 2024 - 2025
TN State Medical License 1995 - 2025
TX State Medical License 1983 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 1998
Top MD Consumers Checkbook

Clinical Trials

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma Start of enrollment: 1996 Jul 01
Completed
Phase 2
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Start of enrollment: 2003 Jan 01
Unknown status
Phase 4
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
RECRUITING
PHASE3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

264 citations
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
Hedy L. Kindler, Nofisat Ismaila, Samuel G. Armato, Raphael Bueno, Mary Hesdorffer
Journal of Clinical Oncology. 2018-01-18
5 citations
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III ...
Nadia Harbeck, Pere Gascón, Clyde M Jones, Allen Nixon, Andriy Krendyukov
Future Oncology. 2017-04-28
16 citations
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer.
Dana Backlund Cardin, Ramya Thota, Laura W. Goff, Jordan Berlin, Clyde M. Jones
American Journal of Clinical Oncology. 2017-03-01

Professional Memberships

American College of Physicians - ACP
Fellow